Next Article in Journal / Special Issue
New Conotoxin SO-3 Targeting N-type Voltage-Sensitive Calcium Channels
Previous Article in Journal / Special Issue
Marine Toxins That Target Voltage-gated Sodium Channels
Open AccessReview

ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential

Institute for Molecular Bioscience, The University of Queensland, St Lucia, 4072, QLD, Australia
*
Author to whom correspondence should be addressed.
Mar. Drugs 2006, 4(3), 193-214; https://doi.org/10.3390/md403193
Received: 16 February 2006 / Accepted: 28 February 2006 / Published: 6 April 2006
(This article belongs to the Special Issue Marine Drugs and Ion Channels)
Highly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain. View Full-Text
Keywords: ω-conotoxin; Structure-Activity relationship; pain ω-conotoxin; Structure-Activity relationship; pain
MDPI and ACS Style

Schroeder, C.I.; Lewis, R.J. ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential. Mar. Drugs 2006, 4, 193-214.

Show more citation formats Show less citations formats

Article Access Map

1
Only visits after 24 November 2015 are recorded.
Back to TopTop